Kapui Z, Mikus E G, Bence J, Gerber K, Boér K, Korbonits D, Borsodi A, Arányi P
Chinoin Pharmaceutical and Chemical Works Co., Ltd., Budapest, Hungary.
Arzneimittelforschung. 1998 Dec;48(12):1147-55.
CH-13584 (formerly: KHL-8425, 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl], CAS 115779-20-9) showed antitussive effect on the citric acid spray-induced cough model. The antitussive effect of p.o. CH-13584 was antagonised by i.m. or intracerebroventricular (i.c.v.) naloxone, i.m. nor-binaltorphimine or s.c. beta-funaltrexamine. Intracerebroventricular administration of CH-13584 induced long-lasting antitussive effect which was antagonised by coadministration of i.c.v. naloxone. CH-13584 did not bind to opioid mu, delta, kappa receptor in vitro or inhibit the [3H]diprenorphine binding in vivo. Two-week treatment with CH-13584 up to the dose of 100 mg/kg p.o. did not produce autonomic and behavioural signs of withdrawal induced either by drug withdrawal or by naloxone injection, while morphine and codeine induced characteristic opioid-type physical dependence in rats.
CH-13584(原名:KHL-8425,1H-嘌呤-2,6-二酮,3,7-二氢-3-甲基-7-[(5-甲基-1,2,4-恶二唑-3-基)甲基],化学物质登记号115779-20-9)在柠檬酸喷雾诱导的咳嗽模型中显示出镇咳作用。口服CH-13584的镇咳作用可被肌肉注射或脑室内注射纳洛酮、肌肉注射去甲二氢吗啡酮或皮下注射β-芬太尼丁拮抗。脑室内注射CH-13584可诱导持久的镇咳作用,该作用可被脑室内注射纳洛酮共同给药所拮抗。CH-13584在体外不与阿片μ、δ、κ受体结合,在体内也不抑制[3H]二丙诺啡结合。用CH-13584以高达100mg/kg的剂量口服治疗两周,不会产生因停药或注射纳洛酮引起的自主和行为戒断症状,而吗啡和可待因会在大鼠中诱导出典型的阿片类身体依赖性。